Valves exist in the body (e.g., in the heart and the systemic veins) to allow unidirectional blood flow. A variety of congenital conditions, infectious diseases (e.g., endocarditis), rheumatic heart disease, and age-related impairments (e.g., senile stenosis) can necessitate implantation of an artificial valve.
One aspect of the invention provides an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. The plurality of leaflets form a plurality of coaptation regions between two adjacent leaflets. The coaptation regions include extensions along a z-axis and adapted and are configured to form a releasable, but substantially complete seal when the leaflets are in a closed position.
This aspect of the invention can have a variety of embodiments. The extensions can have a length along the z-axis between about 1 mm and about 10 mm. The extensions can have a curved profile. The curved profile can lie in an x-y plane. The curved profile can be a variance in extension length along the z-axis.
The coaptation regions can have a substantially hyperbolic profile. Each of the plurality of leaflets can have a substantially elliptical leaflet-stent attachment line. The stent can be an expandable, cylindrical stent. The leaflets can be reinforced with one or more selected from the group consisting of: reinforcing materials and directional fibers. One or more selected from the group consisting of: coaptation regions and leaflet-stent attachment lines can be reinforced with one or more selected from the group consisting of: additional polymer thickness, reinforcing materials, and directional fibers.
Adjacent leaflets can be coupled to a wide post of the stent. The wide post can include one or more windows. The wide post can have a width between about 0.5 mm and about 3 mm.
The stent can include metal or plastic. The metal can be selected from the group consisting of: stainless steel, 316L stainless steel, cobalt-chromium alloys, and nickel-titanium alloys.
The leaflets can be formed from a first polymer. The first polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
The stent can be dip-coated in a second polymer. The second polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof. The leaflets can be coupled to the second polymer. The leaflets can be mechanically coupled to the second polymer. The leaflets can be chemically coupled to the second polymer. The leaflets can be coupled to the second polymer by one or more techniques selected from the group consisting of: gluing, chemical fusing, thermal fusing, sonic welding, stitching, and mechanical fastening.
A leaflet-stent attachment line for each of the plurality of leaflets can substantially approximate a frame of the stent. The leaflet-stent attachment line can lie within about 3 mm of the frame of the stent.
The stent can include one or more anchor points. The anchor points can contain a radio-opaque material.
The valve can be adapted and configured for replacement of one or more cardiac valves selected from the group consisting of: aortic, mitral, tricuspid, and pulmonary.
The valve can be adapted and configured for insertion in a subject's veins in order to treat venous insufficiency. The valve can be adapted and configured for serial expansion as the subject ages.
Another aspect of the invention provides an artificial, flexible valve including: a stent defining a wall and a plurality of leaflets extending from the wall of the stent. Each of the plurality of leaflets terminates in a commissure line. The commissure lines deviate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.
This aspect of the invention can have a variety of embodiments. The leaflets can further include extensions beyond the commissure lines along a z-axis. The extensions can have a length along the z-axis between about 1 mm and about 10 mm. The extensions can have a curved profile. The curved profile can lie in an x-y plane. The curved profile can be a variance in extension length along the z-axis.
Each of the plurality of leaflets can have a substantially elliptical leaflet-stent attachment line. The stent can have an expandable, cylindrical stent. The leaflets can be reinforced with one or more selected from the group consisting of: reinforcing materials and directional fibers.
One or more selected from the group consisting of: coaptation regions and leaflet-stent attachment lines can be reinforced with one or more selected from the group consisting of: additional polymer thickness, reinforcing materials, and directional fibers.
Adjacent leaflets can be coupled to a wide post of the stent. The wide post can include one or more windows. The wide post can have a width between about 0.5 mm and about 3 mm.
The stent can include metal or plastic. The metal can be selected from the group consisting of: stainless steel, 316L stainless steel, cobalt-chromium alloys, and nickel-titanium alloys.
The leaflets can be formed from a first polymer. The first polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
The stent can be dip-coated in a second polymer. The second polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof. The leaflets can be coupled to the second polymer. The leaflets can be mechanically coupled to the second polymer. The leaflets can be chemically coupled to the second polymer. The leaflets can be coupled to the second polymer by one or more techniques selected from the group consisting of: gluing, chemical fusing, thermal fusing, sonic welding, stitching, and mechanical fastening.
A leaflet-stent attachment line for each of the plurality of leaflets can substantially approximate a frame of the stent. The leaflet-stent attachment line can lie within about 3 mm of the frame of the stent.
The stent can include one or more anchor points. The anchor points can contain a radio-opaque material.
The valve can be adapted and configured for replacement of one or more cardiac valves selected from the group consisting of: aortic, mitral, tricuspid, and pulmonary.
The valve can be adapted and configured for insertion in a subject's veins in order to treat venous insufficiency. The valve can be adapted and configured for serial expansion as the subject ages.
Another aspect of the invention provides an artificial, flexible valve including: an expandable, cylindrical stent defining a wall and a plurality of leaflets extending from the wall of the stent. Adjacent leaflets can be coupled to a relatively wide post of the stent.
The leaflets can further include extensions beyond the commissure lines along a z-axis. The extensions can have a length along the z-axis between about 1 mm and about 10 mm. The extensions can have a curved profile. The curved profile can lie in an x-y plane. The curved profile can be a variance in extension length along the z-axis.
The coaptation regions can have a substantially hyperbolic profile. Each of the plurality of leaflets can have a substantially elliptical leaflet-stent attachment line. The leaflets can be reinforced with one or more selected from the group consisting of: reinforcing materials and directional fibers.
One or more selected from the group consisting of: coaptation regions and leaflet-stent attachment lines can be reinforced with one or more selected from the group consisting of: additional polymer thickness, reinforcing materials, and directional fibers.
The relatively wide post can include one or more windows. The relatively wide post can have a width between about 0.5 mm and about 3 mm.
The stent can include metal or plastic. The metal can be selected from the group consisting of: stainless steel, 316L stainless steel, cobalt-chromium alloys, and nickel-titanium alloys.
The leaflets can be formed from a first polymer. The first polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof.
The stent can be dip-coated in a second polymer. The second polymer can be selected from the group consisting of: polytetrafluoroethylene, polyethylene, polyurethane, silicone, and copolymers thereof. The leaflets can be coupled to the second polymer. The leaflets can be mechanically coupled to the second polymer. The leaflets can be chemically coupled to the second polymer. The leaflets can be coupled to the second polymer by one or more techniques selected from the group consisting of: gluing, chemical fusing, thermal fusing, sonic welding, stitching, and mechanical fastening.
A leaflet-stent attachment line for each of the plurality of leaflets can substantially approximate a frame of the stent. The leaflet-stent attachment line can lie within about 3 mm of the frame of the stent.
The stent can include one or more anchor points. The anchor points can contain a radio-opaque material.
The valve can be adapted and configured for replacement of one or more cardiac valves selected from the group consisting of: aortic, mitral, tricuspid, and pulmonary. The valve can be adapted and configured for insertion in a subject's veins in order to treat venous insufficiency. The valve can be adapted and configured for serial expansion as the subject ages. The valve may not contain any animal-derived materials.
Another aspect of the invention provides a mandrel including: a cylindrical profile and a plurality of recesses adapted and configured to define a plurality of leaflets forming a plurality of coaptation regions between two adjacent leaflets. The coaptation regions can include extensions along a z-axis and be adapted and configured to form a releasable, but substantially complete seal when the leaflets are in a closed position.
This aspect of the invention can have a variety of embodiments. The mandrel can include one more cutting guides located between the plurality of recesses. The mandrel can include one or more heating elements.
Another aspect of the invention provides a mandrel including: a cylindrical profile and a plurality of recesses adapted and configured to define a plurality of leaflets. Each of the plurality of leaflets terminate in a commissure line. The commissure lines deviate from a hyperbola formed in the x-y plane by at least one deviation selected from the group consisting of: a deviation in the z-direction and one or more curves relative to the hyperbola.
This aspect of the invention can have a variety of embodiments. The mandrel can include one more cutting guides located between the plurality of recesses. The mandrel can include one or more heating elements.
Another aspect of the invention provides a method for fabricating an artificial, flexible valve. The method includes: dip coating a cylindrical mandrel having a plurality of recesses each approximating a profile of a leaflet and coupling the leaflets to an inner wall of a stent.
This aspect of the invention can have a variety of embodiments. The method can further include dip coating the stent prior to coupling the leaflets to the inner wall of the stent. The stent and the mandrel can have larger diameters than a target location for the valve. The method can further include separating adjacent leaflets from each other.
For a fuller understanding of the nature and desired objects of the present invention, reference is made to the following detailed description taken in conjunction with the accompanying drawing figures wherein like reference characters denote corresponding parts throughout the several views and wherein:
The instant invention is most clearly understood with reference to the following definitions.
As used herein, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.
Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. “About” can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
As used in the specification and claims, the terms “comprises,” “comprising,” “containing,” “having,” and the like can have the meaning ascribed to them in U.S. patent law and can mean “includes,” “including,” and the like.
Unless specifically stated or obvious from context, the term “or,” as used herein, is understood to be inclusive.
Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (as well as fractions thereof unless the context clearly dictates otherwise).
Aspects of the invention provide a novel platform that allows development of polymeric valves of any size and shape. Aspects of the invention can be applied to valves designed for surgical implantation (e.g., through a sternotomy or thoracotomy) or valves designed for percutaneous, transcatheter implantation. Additionally, embodiments of the invention allow for possible percutaneous replacement of a dysfunctional valve, whether in adults or in small children. In addition, if implanted in a child, embodiments of the invention allow the valve to be serially expanded to accompany the child's growth.
Cardiac Applications
Multiple types of congenital heart defects require heart valve replacement surgery in infancy or childhood. In adults, the most commonly replaced valves are aortic and mitral, whereas in children, the pulmonary valve is the most commonly replaced valve. Heart valves are currently replaced using tissue valves (homograft or xenograft) or mechanical metal valves, each having their shortcomings. Homograft valves are in short supply, particularly in sizes suitable for use in children, and biologic tissue-based valves (whether bovine, porcine, or homograft) tend to induce an immunologic reaction which leads to failure of these valves. Mechanical valves generally require anticoagulation, and are almost never used in the pulmonary position due to an increased risk of thrombosis.
Furthermore, none of the surgically implanted valves can adapt to growing patients. The rapid growth of pediatric patients leads them to outgrow their implanted valves within a few years and induces a cycle of frequent surgical valve replacements during childhood. Aspects of the invention provide valves having improved biocompatibility, durability, and hemodynamic performance and would reduce the frequency of recurrent open heart surgeries for valve replacement.
Venous Applications
Additionally, aspects of the invention can be used for venous valve replacement in patients having venous disease such as chronic venous insufficiency (leading to leg swelling). Because the polymer leaflets can be made extremely thin, the valves can even open under extremely low venous pressure gradients.
Artificial, Flexible Valves
Referring now to
The valve 100 will now be described in the context of its components and methods of fabrication.
Stents
Referring now to
Stent 102 can be completely enveloped (e.g., about its external surface ES, as shown in
The stent 102 can be manufactured by laser cutting or wire forming. To increase bonding strength between metal and polymer, roughness of stent surface can be controlled. Some or all open cells 204, 206 of the stent can be covered as the bare 102 stent is dipped into the polymer solution.
The components of stent 102 can have a variety of dimensions that can be selected to achieve a desired flexibility, rigidity, resilience, and the like. For example, the thickness and width of components of the stent 102 can be between about 0.1 mm and about 2 mm.
As discussed above, stent 102 can include one or more vertical posts 110a-110c to enhance bonding with leaflets 106.
Stent 102 can include a plurality of vertical posts 110 that can serve a variety of functions. Some vertical posts 110 can include additional structure and are referred to herein as wide posts 112. Wide posts 112 are preferably located at leaflet joints where two leaflets 106 meet. For example, in a valve 100 having three leaflets 106, wide posts 112 can be positioned at 120° intervals within cylindrical stent 102.
Wide posts 112 provide mechanical support to leaflets and prevent or substantially limit inward deformation of wall 104 due to tensile forces applied to leaflets 106 transferred to wall 104. Without being bound by theory, it is believed that the wide posts 112 provide increased strength and resiliency due to formation of polymer wall 104 through windows 208 and around wide posts 112, thus providing cohesive holding of the polymer to itself around the stent 102 instead of relying solely on adhesive bonding of the polymer wall 104 to the stent 102.
Wide posts 112 advantageously allow for relaxed tolerances in positioning leaflets 106 relative to wide posts 112. For example, window 208 can have a width of between about 0.5 mm and about 3 nun (e.g., about 1 mm) and a height of between about 1 mm and about 10 mm (e.g., about 5 mm).
A variety of additional wide post geometries are depicts in
Referring now to
Referring now to
In one embodiments depicted in
Leaflets
Leaflets 106 can be formed using a variety of techniques including dip coating, 3D-printing (also known as additive manufacturing), molding, and the like.
Referring now to
The mandrel 900 for the leaflets 106 can have novel features, including edges representing the leaflet attachment points that are mathematically defined and leaflet tips that are extended in order to increase the coaptation length of the leaflets (including a curved portion CP and a linear portion LP, as shown in
Mandrel 900 can be designed to have a complementary geometry to the desired leaflet shape and permits easier viewing of leaflet geometry. Although mandrel 900 is utilized to describe the geometry of the leaflet 106, it should be recognized that the upstream surface of the resulting leaflets will have this geometry when formed by dip coating and that the complementary geometry of the leaflet(s) 106 can be produced using techniques other than dip coating. Mandrel 900 is preferably cylindrical and can have an outer profile substantially approximating an inner profile of stent 102. Mandrel 900 can define a plurality of pockets 902 that each define a leaflet 106 as it hangs from wall 104 via attachment line 108. Each leaflet 106 terminates in a commissure line 904 often, but not necessarily lying in a plane at the point where the elliptical or parabolic curve ends and where the leaflet often contacts the other leaflets. A substantially vertical coaptation region 906 can extend beyond the commissure line 904 to an extended commissure line 912 for improved sealing as will be discussed herein.
Referring now to
Referring now to
As seen in
Referring now to
The zone of coaptation is affected by the pressure placed upon the closed valve 100. The higher the pressure, the more downward tension is placed on the leaflets 106, possibly leading to a failure of coaptation with consequent regurgitation. Proper coaptation also allows the leaflets 106 to support each other, so there is less stress placed on any individual leaflet 106. Another benefit of enhancing height of the coaptation zone is that this allows the valve 100 to be re-dilated to a larger diameter late after implantation (such as to accommodate growth of a pediatric patient), while still maintaining competence of the valve 100.
Options for enhancing the height of the coaptation zone include creating excess length of the leaflet free edges, so that the free edge length is greater than twice the radius of the stent or mandrel depicted in
Referring now to
Referring now to
Referring now to
Referring now to
In order to increase tear-resistance of the leaflets 106 and enhance bonding strength between leaflets 106 and stent 102, the thickness of the leaflets 106 can be controlled regionally. Because the most common failure points are at the outer edges of the leaflets 106 (such as commissure line 904 or extended commissure line 912 and leaflet-stent attachment line 108), increased thickness at outer areas of the leaflets 106 can improve the strength and durability. Also, if local areas are expected to have concentrated stress, the areas can be locally reinforced (e.g., made thicker than other areas). The thickness can be smoothly increased. The width of thickened area along leaflet-stent attachment line 108 can be large enough to cover the glued area for bonding the leaflets 106 and the covered stent 102. In some embodiments, the thickness of thickened areas of the leaflets is between about 0.1 mm and about 1 mm.
Multiple dippings can be performed to produce leaflets with a desired thickness. In some embodiments, the thickness of the leaflets is between about 0.01 mm and about 0.2 mm.
Different reinforcing materials such as strips, fibers and particles can be placed between the layers, or directly mixed into the polymer solution. The inserted material(s) can prevent tearing and reduce propagation of the tear if it occurs. The materials can have directional properties and can be layered onto, or embedded into, the leaflets in an optimal direction to prevent or limit tears.
Referring now to
After dipping the mandrel 900 into the polymer solution, the coated polymer dries in order to form the leaflet(s) 106. Because the formed leaflets 106 are connected, they need to be separated from each other. These can be cut by a sharp cutter (e.g., a knife, a scalpel, a razor blade, a utility knife, and the like), a heated iron, a laser, a rotary tool, and the like. A guide on the top surface of the mandrel for cutting provides a clear, easy, and safe cutting path. The guide can be grooved/concave or convex. Also, the commissure edges of the mandrel can be sharp like a blade to facilitate leaflet separation and to improve on the quality of the cut edges.
Referring now to
The stent-mounted valve 100 can be implanted with smaller diameter than its manufactured diameter for reducing leakage and improving durability.
Methods of Fabricating Valves
Referring now to
In some embodiments, the stent 102 can be first coated with a polymer such as PEEK or other metal surface modifier prior to further dip coating of the stent 102 in another polymer in order to improve adhesion of the leaflet polymer 106 to the metal stent 102.
The bare mandrel 900 can optionally be coated with a release agent to promote separation of the polymer leaflets from the mandrel 900.
Both the bare stent 102 and the mandrel 900 are dip coated separately in a polymer, which may be the same or different for the bare stent 102 and the mandrel 900.
The leaflets 106 formed on the mandrel 900 can be removed prior to introduction to the coated stent. Alternatively, the coated mandrel 900 can be introduced into the coated stent, the leaflets 106 can be bonded to the coated stent, and the mandrel 900 can be then be removed to leave the assembled valve 100.
Leaflets 106 can be bonded to the dip-coated stent using a variety of techniques including gluing, chemical fusing (i.e., dissolving the polymers) thermal fusing, sonic welding, stitching, mechanical fastening, and the like. For example, the same polymer solution used to coat either bare stent 102 and/or mandrel 900 can be applied to bond the leaflets 106 to the dip-coated stent.
Although separate fabrication of the polymer-coated stent and the leaflets 106 are currently preferred as a means of avoiding or minimizing air bubbles, the entire valve could be formed in a single dip coating (or series of dip coatings) through use of production-grade manufacturing techniques and other optimizations.
Although dipcoating was successfully used to fabricate prototypes of the valves described herein, any other manufacturing technique capable of producing flexible leaflets can be utilized. Exemplary techniques include injection molding and additive manufacturing or 3D printing.
Referring now to
As can be seen in
Referring now to
Polymers
The leaflets 106 can be formed from the same or different polymer with which the stent 102 is coated to form wall 104. For example, the leaflets 106 can be formed from polymers such as polyethylene, polyurethane, silicone, and the like. Wall 104 can be formed from polyethylene, polyurethane, silicone, and the like.
Supplementary materials such as directional fibers can mixed into the polymer solution or applied to the leaflets between coatings in order to increase durability
The selected polymer can be dissolved by a solvent such as tetrahydrofuran or dimethylacetamide. The thickness of the coated polymer can be controlled as a function of the density of the polymer solution and total number of dippings. When the polymer becomes dry after dipping, the coated stent and mandrel can be placed horizontally and axially rotated in order to produce a constant thickness and prevent the polymer from dripping.
Implantation of Valves
Referring now to
In step S1802, the valve is placed over an expander and within a sheath. Various surgical expanders and access devices exist in the cardiac surgery field. For example, a balloon catheter could be introduced into a patient's femoral artery and guided to the location of the implanted valve (e.g., within the patient's heart or systemic veins).
In step S1804, the sheath (containing the valve and the expander) is introduced into a vessel of the subject.
In step S1806, the valve and the expander are advanced from the sheath and positioned in the desired location.
In step S1808, the desired positioning can be verified using various imaging techniques such as fiber optics, ultrasound, X-ray, and the like.
In step S1810, the expander is actuated within the valve to expand the valve to form a press fit against the vessel in which the valve is implanted. For example, a balloon catheter can be expanded by introducing gas or a liquid into the balloon.
In step S1812, the desired positioning and expansion can be verified using various imaging techniques such as fiber optics, ultrasound, X-ray, and the like.
In step S1814, the expander and sheath can be retracted according to standard surgical techniques.
Expansion of Implanted Valves
Referring now to
In step S1902, an expander is introduced into the implanted valve.
In step S1904, the expander is actuated within the implanted valve to increase the diameter of the implanted valve.
In step S1906, the desired expansion can be verified using various imaging techniques.
In step S1908, the expander can be retracted according to standard surgical techniques.
Surgically-Implanted Valves
Although embodiments of the invention are described and depicted in the context of percutaneous, transcatheter valves having expandable, cylindrical stents, embodiments of the invention described herein can be applied to surgically-implanted valves that generally include anchors having fixed-diameter anchors supporting a plurality of leaflets (e.g., the CARPENTIER-EDWARDS™ series of valves available from Edwards Lifesciences Corporation of Irvine, Calif.). In such embodiments, the anchor replaces the expandable, cylindrical stents described herein.
Although preferred embodiments of the invention have been described using specific terms, such description is for illustrative purposes only, and it is to be understood that changes and variations may be made without departing from the spirit or scope of the following claims.
The entire contents of all patents, published patent applications, and other references cited herein are hereby expressly incorporated herein in their entireties by reference.
This application is a continuation of U.S. patent application Ser. No. 16/563,229, filed Sep. 6, 2019, which is a continuation of U.S. patent application Ser. No. 15/308,667, filed Nov. 3, 2016, which is a 371 national stage entry of International Application No. PCT/US2015/029442, filed May 6, 2015, which claims priority to U.S. Provisional Patent Application Ser. No. 61/989,820, filed May 7, 2014. The entire content of these applications is hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3655306 | Ross et al. | Apr 1972 | A |
3657744 | Ersek | Apr 1972 | A |
3744060 | Bellhouse et al. | Jul 1973 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4731074 | Rousseau et al. | Mar 1988 | A |
4778461 | Pietsch et al. | Oct 1988 | A |
5326371 | Love et al. | Jul 1994 | A |
5411552 | Andersen et al. | May 1995 | A |
5500016 | Fisher | Mar 1996 | A |
5509930 | Love | Apr 1996 | A |
5562729 | Purdy et al. | Oct 1996 | A |
5674279 | Wright et al. | Oct 1997 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
6086612 | Jansen | Jul 2000 | A |
6092529 | Cox | Jul 2000 | A |
6113631 | Jansen | Sep 2000 | A |
6117169 | Moe | Sep 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6171335 | Wheatley et al. | Jan 2001 | B1 |
6206911 | Milo | Mar 2001 | B1 |
6270526 | Cox | Aug 2001 | B1 |
6299637 | Shaolian et al. | Oct 2001 | B1 |
6454798 | Moe | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6562069 | Cai et al. | May 2003 | B2 |
6582462 | Andersen et al. | Jun 2003 | B1 |
6596024 | Chinn | Jul 2003 | B2 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6716241 | Wilder et al. | Apr 2004 | B2 |
6736845 | Marquez et al. | May 2004 | B2 |
6911043 | Myers et al. | Jun 2005 | B2 |
6916338 | Speziali | Jul 2005 | B2 |
6953332 | Kurk et al. | Oct 2005 | B1 |
6958076 | Acosta et al. | Oct 2005 | B2 |
7018408 | Bailey et al. | Mar 2006 | B2 |
7041132 | Quijano et al. | May 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7125418 | Duran et al. | Oct 2006 | B2 |
7160320 | Duran | Jan 2007 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7261732 | Justino | Aug 2007 | B2 |
7329279 | Haug et al. | Feb 2008 | B2 |
7338520 | Bailey et al. | Mar 2008 | B2 |
7510572 | Gabbay | Mar 2009 | B2 |
7510575 | Spenser et al. | Mar 2009 | B2 |
7534259 | Lashinski et al. | May 2009 | B2 |
7547322 | Sarac et al. | Jun 2009 | B2 |
7556645 | Lashinski et al. | Jul 2009 | B2 |
7569071 | Haverkost et al. | Aug 2009 | B2 |
7604661 | Pavcnik et al. | Oct 2009 | B2 |
7618446 | Andersen et al. | Nov 2009 | B2 |
7628803 | Pavcnik et al. | Dec 2009 | B2 |
7648527 | Agnew | Jan 2010 | B2 |
7682389 | Beith | Mar 2010 | B2 |
7799069 | Bailey et al. | Sep 2010 | B2 |
7803185 | Gabbay | Sep 2010 | B2 |
7806920 | Duran | Oct 2010 | B2 |
7833565 | O'Connor et al. | Nov 2010 | B2 |
8109996 | Stacchino et al. | Feb 2012 | B2 |
8216631 | O'Connor et al. | Jul 2012 | B2 |
8246678 | Salahieh et al. | Aug 2012 | B2 |
8512397 | Rolando et al. | Aug 2013 | B2 |
8535373 | Stacchino et al. | Sep 2013 | B2 |
8540768 | Stacchino et al. | Sep 2013 | B2 |
8613763 | Pavcnik et al. | Dec 2013 | B2 |
9259313 | Wheatley | Feb 2016 | B2 |
9421100 | Bailey et al. | Aug 2016 | B2 |
9603707 | Li | Mar 2017 | B2 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010010017 | Letac et al. | Jul 2001 | A1 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010025196 | Chinn et al. | Sep 2001 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020151971 | Cox | Oct 2002 | A1 |
20030036795 | Andersen et al. | Feb 2003 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030097175 | O'Connor | May 2003 | A1 |
20030109924 | Cribier | Jun 2003 | A1 |
20030114924 | Moe | Jun 2003 | A1 |
20040088045 | Cox | May 2004 | A1 |
20040088046 | Speziali | May 2004 | A1 |
20040106976 | Bailey et al. | Jun 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040215333 | Duran et al. | Oct 2004 | A1 |
20050055079 | Duran | Mar 2005 | A1 |
20050137676 | Richardson et al. | Jun 2005 | A1 |
20050137681 | Shoemaker et al. | Jun 2005 | A1 |
20050209689 | Speziali | Sep 2005 | A1 |
20050267560 | Bates | Dec 2005 | A1 |
20050283231 | Haug et al. | Dec 2005 | A1 |
20060020333 | Lashinski et al. | Jan 2006 | A1 |
20060020334 | Lashinski et al. | Jan 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060089708 | Osse et al. | Apr 2006 | A1 |
20060122693 | Biadillah et al. | Jun 2006 | A1 |
20060200234 | Hines | Sep 2006 | A1 |
20060206192 | Tower et al. | Sep 2006 | A1 |
20060241744 | Beith | Oct 2006 | A1 |
20060282157 | Hill et al. | Dec 2006 | A1 |
20070010877 | Salahieh et al. | Jan 2007 | A1 |
20070027535 | Purdy, Jr. et al. | Feb 2007 | A1 |
20070050013 | Gross | Mar 2007 | A1 |
20070050014 | Johnson | Mar 2007 | A1 |
20070050021 | Johnson | Mar 2007 | A1 |
20070061009 | Spenser et al. | Mar 2007 | A1 |
20070078510 | Ryan | Apr 2007 | A1 |
20070129788 | Drasler et al. | Jun 2007 | A1 |
20070208550 | Cao et al. | Sep 2007 | A1 |
20070213813 | Von Segesser et al. | Sep 2007 | A1 |
20070282436 | Pinchuk | Dec 2007 | A1 |
20070288087 | Fearnot et al. | Dec 2007 | A1 |
20080086204 | Rankin | Apr 2008 | A1 |
20080091261 | Long et al. | Apr 2008 | A1 |
20080161911 | Revuelta et al. | Jul 2008 | A1 |
20080200980 | Robin et al. | Aug 2008 | A1 |
20090062907 | Quijano et al. | Mar 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090171456 | Kveen et al. | Jul 2009 | A1 |
20090222085 | Kumar | Sep 2009 | A1 |
20090248149 | Gabbay | Oct 2009 | A1 |
20090254177 | Yang et al. | Oct 2009 | A1 |
20090281609 | Benichou et al. | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090287296 | Manasse | Nov 2009 | A1 |
20090287299 | Tabor et al. | Nov 2009 | A1 |
20090292350 | Eberhardt et al. | Nov 2009 | A1 |
20100004740 | Seguin et al. | Jan 2010 | A1 |
20100005658 | Haverkost et al. | Jan 2010 | A1 |
20100018447 | Holecek et al. | Jan 2010 | A1 |
20100055149 | Li et al. | Mar 2010 | A1 |
20100057191 | Pavcnik et al. | Mar 2010 | A1 |
20100057194 | Ryan | Mar 2010 | A1 |
20100076548 | Konno | Mar 2010 | A1 |
20100094411 | Tuval et al. | Apr 2010 | A1 |
20100114307 | Agnew et al. | May 2010 | A1 |
20100131055 | Case et al. | May 2010 | A1 |
20100145435 | Voinov et al. | Jun 2010 | A1 |
20100152839 | Shandas et al. | Jun 2010 | A1 |
20100168832 | Neuenschwander | Jul 2010 | A1 |
20100174362 | Straubinger et al. | Jul 2010 | A1 |
20100204781 | Alkhatib | Aug 2010 | A1 |
20100204785 | Alkhatib | Aug 2010 | A1 |
20100211165 | Schreck | Aug 2010 | A1 |
20100249894 | Oba et al. | Sep 2010 | A1 |
20100286769 | Andersen et al. | Nov 2010 | A1 |
20100305685 | Millwee et al. | Dec 2010 | A1 |
20110257738 | Corbett et al. | Oct 2011 | A1 |
20110257739 | Corbett | Oct 2011 | A1 |
20120053676 | Ku et al. | Mar 2012 | A1 |
20120078347 | Braido et al. | Mar 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120179244 | Schankereli et al. | Jul 2012 | A1 |
20120197390 | Alkhatib | Aug 2012 | A1 |
20120277856 | Spenser et al. | Nov 2012 | A1 |
20130073037 | Gregg et al. | Mar 2013 | A1 |
20130085566 | Forster et al. | Apr 2013 | A1 |
20130160512 | Chen | Jun 2013 | A1 |
20130325116 | Sundler et al. | Dec 2013 | A1 |
20140005772 | Edelman et al. | Jan 2014 | A1 |
20140005773 | Wheatley | Jan 2014 | A1 |
20140031927 | Bruchman et al. | Jan 2014 | A1 |
20140107772 | Li et al. | Apr 2014 | A1 |
20140316516 | Vidlund et al. | Oct 2014 | A1 |
20140330367 | Thapliyal | Nov 2014 | A1 |
20150088250 | Zeng et al. | Mar 2015 | A1 |
20160067038 | Park | Mar 2016 | A1 |
20160158000 | Granada et al. | Jun 2016 | A1 |
20170014228 | Emani et al. | Jan 2017 | A1 |
20170086971 | Braido et al. | Mar 2017 | A1 |
20170189172 | Grundeman et al. | Jul 2017 | A1 |
20170189175 | Justino | Jul 2017 | A1 |
20190117391 | Humair | Apr 2019 | A1 |
20190133764 | Carr | May 2019 | A1 |
20190282360 | Colavito | Sep 2019 | A1 |
20190374339 | Bennett | Dec 2019 | A1 |
20190388221 | Lee | Dec 2019 | A1 |
20200000581 | Justing et al. | Jan 2020 | A1 |
20210137676 | Kheradvar | May 2021 | A1 |
Number | Date | Country |
---|---|---|
19546692 | Nov 2002 | DE |
1395205 | Jul 2008 | EP |
WO-0141679 | Jun 2001 | WO |
WO-021 00301 | Dec 2002 | WO |
WO-2012110767 | Aug 2012 | WO |
WO-2013019416 | Feb 2013 | WO |
WO-2014209232 | Dec 2014 | WO |
WO-2015171743 | Nov 2015 | WO |
Entry |
---|
Bavaria, J. E. et al., “The St Jude Medical Trifecta aortic pericardial valve: Results from a global, multicenter, prospective clinical study,” The Journal of Thoracic and Cardiovascular Surgery, 147(2):590-597 (Feb. 2014). |
Claiborne, T. E. et al., “Polymeric trileaflet prosthetic heart valves: evolution and path to clinical reality,” Expert Rev. Med. Devices, 9(6):577-594 (Nov. 2012). |
Cribier, A. et al., “Early Experience With Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients With Calcific Aortic Stenosis,” Journal of the American College of Cardiology, 43(4):698-703 (2004). |
De Tullio, M. D., et al., “Direct numerical simulation of the pulsatile flow through an aortic bileaflet mechanical heart valve,” J. Fluid Meeh., 622:259-290 (Mar. 2009). |
Extended European Search Report for European Patent Application No. 15789240.7, dated Feb. 23, 2018, 9 pages. |
International Search Report and Written Opinion for International Patent Application No. PCT/US2015/029442, dated Nov. 9, 2015, 13 pages. |
Jiang, H. et al., “Design and manufacture of a polyvinyl alcohol (PVA) cryogel tri-leaflet heart valve prosthesis,” Medical Engineering & Physics, vol. 26, pp. 269-277, 2004. |
Leat, M. E., et al., “A synthetic leaflet heart valve with improved opening characteristics,” Med. Eng. Phys., 16:170-476 (Nov. 1994). |
Leat, M. E. et al., “The influence of manufacturing methods on the function and performance of a synthetic leaflet heart valve,” Proc Instn Meeh Engrs, 209:65-69 (1995). |
Leo, H. L., “An In Vitro Investigation of the Flow Fields Through Bileaflet and Polymeric Prosthetic Heart Valves,” A Dissertation Presented to the Academic Faculty In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in Biomedical Engineering, Georgia Institute of Technology, Apr. 2005. |
Mackay, T. G. et al., “New polyurethane heart valve prosthesis: design, manufacture and evaluation,” Biomaterials, 17:1857-1863 (1996). |
MedGadget, “Sorin Mitroflow Aortic Heart Valve With New Phospholipid Reduction Treatment Approved by FDA,” [Online], http://medgadget.com/2014/04/sorin-mitroflow-aortic-heart-valve-with-new-phospholipid-reduction-treatment-approved-by-fda.html, Retrieved on May 2014. |
Metzner, A. et al., “Percutaneous pulmonary polyurethane valved stent implantation,” The Journal of Thoracic and Cardiovascular Surgery, 139(3):748-752 (Mar. 2010). |
Office Action for U.S. Appl. No. 15/308,667, dated Feb. 14, 2018, 14 pages. |
Office Action for U.S. Appl. No. 15/308,667, dated Oct. 9, 2018, 16 pages. |
Office Action for U.S. Appl. No. 16/563,229, dated Apr. 7, 2020, 28 pages. |
Office Action for U.S. Appl. No. 16/563,229, dated Dec. 20, 2019, 22 pages. |
Office Action for U.S. Appl. No. 16/563,229, dated Feb. 22, 2021, 25 pages. |
Permanyer, E. et al., “St. Jude Medical Trifecta™ aortic valve perioperative performance in 200 patients,” Interactive Cardiovascular and Thoracic Surgery, 17:669-673 (2013). |
Sanders, E. H. et al., “Composite Finite Element Model of a Stented Bioprosthetic Heart Valve,” 291-302, Apr. 7, 2015. |
U.S. Food and Drug Administration, St. Jude Medical Trifecta Valve—P100029, [Online], http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/De . . . , Retrieved May 2016. |
Valocik, G. et al., “Three-Dimensional Echocardiography in Mitral Valve Disease,” Eur J Echocardiogr, 6:443-454 (2005). |
Webb, J. G. et al., “Transcatheter Aortic Valve Replacement for Bioprosthetic Aortic Valve Failure The Valve-in-Valve Procedure,” Circulation, 127:2542-2550 (Jun. 2013). |
Zilla, P. et al., “Prosthetic heart valves: Catering for the few,” Biomaterials, 29:385-406 (2008). |
Office Action for U.S. Appl. No. 17/478,665, dated Jan. 21, 2022, 17 pages. |
Office Action for Canadian Application No. 2,948,179, dated Mar. 1, 2022, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20220117731 A1 | Apr 2022 | US |
Number | Date | Country | |
---|---|---|---|
61989820 | May 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16563229 | Sep 2019 | US |
Child | 17473653 | US | |
Parent | 15308667 | US | |
Child | 16563229 | US |